Doripenem hydrate
|
|
|
- CAS-Nr.
- 364622-82-2
- Englisch Name:
- Doripenem hydrate
- Synonyma:
- Finibax;2H5]-Doripenem;DoripeneM Crude;doripenem hydrate;S 4661 monohydrate;Doripenem Hydrate (S 4661);Doripenem hydrate USP/EP/BP;Doripenem monohydrate, >=99%;DORIPENEM MONOHYDRATE STERILE;Doripenem Hydrate/Doribax/S-4661/Finibax
- CBNumber:
- CB0511313
- Summenformel:
- C15H26N4O7S2
- Molgewicht:
- 438.51
- MOL-Datei:
- 364622-82-2.mol
|
Doripenem hydrate Eigenschaften
- Schmelzpunkt:
- 173°C(dec.)(lit.)
- storage temp.
- 2-8°C
- Löslichkeit
- H2O: soluble5mg/mL, clear (warmed)
- Aggregatzustand
- powder
- Farbe
- white to beige
- PH
- Dissolve 0.3g of Doripenem Hydrate in 30mL of water: the pH of the solution is between 4.5 and 6.0.
- BRN
- 15340136
- InChIKey
- NTUBEBXBDGKBTJ-WGLOMNHJSA-N
- CAS Datenbank
- 364622-82-2(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| WGK Germany |
3 |
|
|
| HS Code |
2935.90.9500 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H341 |
Kann vermutlich genetische Defekte verursachen. |
Keimzellmutagenität |
Kategorie 2 |
Warnung |
|
P201,P202, P281, P308+P313, P405,P501 |
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
| P281 |
Vorgeschriebene persönliche Schutzausrüstung verwenden. |
| P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
| P405 |
Unter Verschluss aufbewahren. |
| P501 |
Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Doripenem hydrate Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Doripenem hydrate is a carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.
Doripenem hydrate was first approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on July 25, 2005, then approved by the U.S. Food and Drug Administration (FDA) on Oct 12, 2007, and approved by European Medicines Agency (EMA) on July 25, 2008. It was developed by Shionogi and Janssen, then marketed as Finibax® in Japan and as Doribax® in the US by Shionogi and as Doribax® by Janssen in BE.
Chemische Eigenschaften
Doripenem Hydrate occurs as a white to pale yellow-brown-white crystalline powder. It is sparingly soluble in water, slightly soluble in methanol, and practically insoluble in ethanol (99.5). It is gradually colored to pale yellow-brown-white by light.
Verwenden
Doripenem (doripenem monohydrate) is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup of carbapenems. It is particularly active against Pseudomonas aeruginosa
Biochem/physiol Actions
Doripenem is an ultra-broad spectrum carbopenem antibiotic. Doripenem is active against both gram-positive and gram-negative bacteria.
Doripenem hydrate Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Doripenem hydrate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 217)Lieferanten
364622-82-2()Verwandte Suche:
- (+)-(4r,5s,6s)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[(3s,5s)-5-[(sulfamoylamino)-methyl]-3-pyrrolidinyl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid hydrate
- doripenem hydrate
- DoripeneM Crude
- 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[[(aminosulfonyl)amino]methyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, hydrate
- (4R,5S,6S)-6-[(1R)-1-Hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
- Doripenem monohydrate, >=99%
- (4R,5S,6S)-6-((R)-1-Hydroxyethyl)-4-methyl-7-oxo-3-(((3S,5S)-5-((sulfamoylamino)methyl)pyrroli
- S 4661 monohydrate
- (4R,5S,6S)-6-((R)-1-Hydroxyethyl)-4-methyl-7-oxo-3-(((3S,5S)-5-((sulfamoylamino)methyl)pyrrolidin-3-yl)thio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid hydrate
- Doripenem hydrate USP/EP/BP
- DORIPENEM MONOHYDRATE STERILE
- Doripenem Hydrate (S 4661)
- Doripenem monohydrateQ: What is
Doripenem monohydrate Q: What is the CAS Number of
Doripenem monohydrate Q: What is the storage condition of
Doripenem monohydrate
- 2H5]-Doripenem
- 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[[(aminosulfonyl)amino]methyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, hydrate (1:1), (4R,5S,6S)-
- (4R,5S,6S)-3-[[(3S,5S)-5-[[(aminosulfonyl)amino]methyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid hydrate (1:1)
- Doripenem Hydrate/Doribax/S-4661/Finibax
- Finibax
- 364622-82-2
- 34622-82-2
- C15H24N4O6S2H2O
- C15H26N4O7S2
- Doribax, Doripenem monohydrate, S-4661, Finibax
- Inhibitors
